More on RVNC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.65 |
|
|||
| Open | $3.65 | ||||
| 52 Wk High | $41.12 | ||||
| 52 Wk Low | $12.35 | ||||
| Day High | $3.65 | ||||
| Day Low | $3.65 | ||||
| P/E | N/A | ||||
| EPS | $-27.14 | ||||
| Volume | 18,182 | ||||
- RVNC DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action - RVNC
- RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- RVNC DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action - RVNC
- RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- RVNC DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action - RVNC
- RVNC DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action - RVNC
- Form 15-12G Revance Therapeutics,
- Form SCHEDULE 13G/A Revance Therapeutics, Filed by: Palo Alto Investors LP
- Form S-8 POS Revance Therapeutics,
- Form S-8 POS Revance Therapeutics,
Entities mentioned with RVNC
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Cowen & Co | View Related Stories »
- PDUFA | View Related Stories »
- Goldman Sachs | View Related Stories »
- Needham & Company | View Related Stories »
- Show More...
